Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Revenue of Iovance Biotherapeutics, Inc. (IOVA)
Revenue in 2023 (TTM): $1.19 M
According to Iovance Biotherapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $1.19 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Iovance Biotherapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $1.19 M | $-9,566,000 | $-427,432,000 | $-447,516,000 | $-444,037,000 |
| 2022 | $ | $-21,135,000 | $-374,758,000 | $-395,893,000 | $-389,923,000 |
| 2021 | $ | $-13,980,000 | $-328,272,000 | $-342,252,000 | $-327,821,000 |
| 2020 | $ | $-8,712,000 | $-250,869,000 | $-259,581,000 | $-257,225,000 |
| 2019 | $ | $-8,122,999 | $-189,433,000 | $-197,556,000 | $-187,071,000 |
| 2018 | $ | $-956,000 | $-122,624,000 | $-123,580,000 | $-123,580,000 |
| 2017 | $ | $-952,000 | $-91,112,000 | $-92,064,000 | $-92,064,000 |
| 2016 | $ | $-978,000 | $-51,916,000 | $-52,894,000 | $-52,894,000 |
| 2015 | $ | $-999,000 | $-26,661,000 | $-27,660,000 | $-27,660,000 |
| 2014 | $ | $-9,335,772 | $-11,946,488 | $-12,034,709 | $-12,034,709 |
| 2013 | $ | $-4,655,149 | $-24,929,546 | $-25,381,363 | $-25,381,363 |
| 2012 | $ | $-6,476,546 | $508.81 K | $-3,307,619 | $-3,307,619 |
| 2011 | $ | $-19,302,721 | $-20,539,889 | $-25,694,100 | $-25,694,100 |
| 2010 | $ | $ | $-1,549,393 | $-1,607,988 | $-1,607,988 |
| 2009 | $ | $ | $-14,440 | $-15,772 | $-15,772 |
| 2008 | $ | $ | $-55,808 | $-57,140 | $-57,140 |